Is a
Patent attributes
Patent Jurisdiction
Patent Number
Date of Patent
November 30, 2021
Patent Application Number
15735289
Date Filed
June 13, 2016
Patent Citations Received
Patent Primary Examiner
Patent abstract
Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
